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Abstract
Background The Child–Turcotte–Pugh (CTP) score is a
widely used and validated predictor of long-term survival
in cirrhosis. However, the cutpoints for stratifying labora-
tory variables in CTP have never been validated.
Objective The objective of this study was to identify evi-
dence-based cutpoints for the CTP laboratory subscores to
improve its predictive capacity for transplant-free survival.
Design Retrospective observational study.
Data Source Using a cohort of 30,897 cirrhotic US
Veteran patients with at least 5 years of follow-up, we
performed Cox proportional hazard survival model itera-
tions varying the upper and lower cutpoints for INR, total
bilirubin and albumin CTP subscores. Cutpoints yielding
the highest Harrell’s C-statistics for concordance with
transplant-free survival were incorporated into a modified
CTP (mCTP) score. Validation of the mCTP was per-
formed at multiple time frames within the follow-up period
of the cohort and within subsets defined by disease
etiology.
Results Modification of CTP cutpoints increased the Har-
rell’s C-statistic for age- and gender-adjusted Cox pro-
portional hazard models from 0.701 ± 0.002 to
0.709 ± 0.002 and the risk ratio per unit change from 1.49
(1.48–1.50) to 1.53 (1.52–1.54). The modified cutpoints
showed superiority in predicting 5-year transplant-free
survival in various disease etiology subgroups. A mCTP
substituting serum creatinine for INR performed superiorly
for predicting 5-year transplant-free survival.
Conclusion We propose an evidence-based recalibration of
CTP score cutpoints that optimizes this model’s capacity to
predict transplant-free survival in patients with cirrhosis.
The CTP score remains the best predictor of 5-year overall
and transplant-free survival in patients with cirrhosis.
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Introduction
The Child–Turcotte–Pugh (CTP) score is a widely used and
validated predictor of long-term survival in cirrhosis [1].
Described initially by Child and Turcotte [2] and modified
by Pugh et al. [3], the CTP has undergone several addi-
tional modifications, most recently to change the cutpoint
for serum albumin levels based on laboratory normal value
ranges [4]. While highly predictive of surgical risks [5–9],
hospital mortality [10, 11], post-embolization mortality
[12, 13], transplantation waitlist mortality [14], and long-
term survival [15] in cirrhosis, its major limitations are the
dependence upon subjective variables and convenience-
based cutpoints that have never been validated formally
[4].
The Veterans Outcomes and Costs Associated with
Liver Disease Study Group (VOCAL) recently developed
and validated a method to calculate CTP scores [16] from
administrative datasets, designated as the electronic CTP
(eCTP). The VOCAL cohort includes over 59,000 Veterans
with prevalent cirrhosis treated between the years 2008 and
2010 for whom baseline demographics, disease etiology,
and overall and transplant-free survival data have been
determined. By creating operational definitions for the
subjective CTP variables (ascites and encephalopathy), we
demonstrated that the eCTP score was superior to the
model for end-stage liver disease (MELD) score, Charl-
son–Deyo index, VACS index [17], and CirCom score [18]
for prediction of 5-year overall and transplant-free survival
in this cohort.
Given the size of the cohort and comprehensive follow-
up, the cohort appeared ideal for testing the hypothesis that
the current CTP laboratory cutpoint values are not opti-
mized for predicting survival in cirrhosis. We therefore
performed serial modifications of the eCTP varying the
upper and lower cutpoints for INR, total bilirubin and
serum albumin to determine the impact of concordance
with transplant-free survival in Cox proportional hazard
survival models. We found that current cutpoints indeed do
not optimally predict transplant-free survival, and we
define cutpoints that provide better concordance with sur-
vival models. Compared to MELD, the current scoring
system used for liver transplant allocation, both original
and modified CTP (mCTP) are far superior predictors of




The derivation of the VOCAL cohort has previously been
described [16]. Using the Veterans Health Administration
(VHA) Corporate Data Warehouse (CDW) with local IRB
approvals at each site, data from all patients with cirrhosis
using a validated algorithm (two outpatient or one inpatient
ICD9-CM code for cirrhosis [571.2, 571.5]) [19] from the
period of 1/1/2008 to 12/31/2010 were obtained. For these
individuals, we obtained all in- and outpatient ICD9-CM
codes, CPT codes, pharmacy data, and laboratory values
from 1/1/2002 to 12/31/2013. Death was ascertained using
the Vital Status File (censoring as of December 31, 2014).
Liver transplantation status was obtained by cross-refer-
encing United Network of Organ Sharing/Organ Procure-
ment and Transplantation Network STAR-file data [20].
For non-laboratory CTP subscores, we utilized our previ-
ously validated algorithm incorporating pharmacy data,
CPT codes, and ICD9 codes to determine the presence and
severity of ascites and encephalopathy [16]. Laboratory
values close to the end date of the specified quarter of
analysis (e.g., 3/31/2008 for first quarter 2008) were used,
and the duration of survival was calculated from the quarter
end-date as previously described [16].
Modified Child–Turcotte–Pugh (mCTP) Score
Iterations
Using R survival package [21, 22], and year 2008 quarter 1
data, mCTP scores were derived for serial modifications of
the lower cutpoint of INR (from 1.0 to 4.0), the upper
cutpoint of INR (from 2.0 to 5.0), the lower cutpoint of
total bilirubin (from 1.0 to 4.0), the upper cutpoint of total
bilirubin (from 2.0 to 5.0), the lower cutpoint of serum
albumin (from 1.0 to 4.0), and the upper cutpoint of serum
albumin (from 2.5 to 4.5). Ascites and encephalopathy
eCTP subscores were held constant based on previous
operational definitions [16]. The discriminative capability
of each CTP score in Cox proportional hazards regression
models adjusting for gender and age was evaluated using
the concordance system of Harrell et al. [23] Optimal
cutpoints were identified then validated in dataset from
2008 quarters 2–4 as well as evaluated for concordance in
various patient subsets. The mCTP models were also
compared to the original CTP (oCTP) score, a proposed
modification of the CTP (Huo CTP) developed in Taiwan
[24], and MELD score. Results were also confirmed by
using competing risk models in R (mstate package
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[21, 25]). Due to relatively lower LogWorth scores in
multivariable models for the INR and encephalopathy
subscores, a 5–13-point CTP model (mCTP [13]) in which
the INR and hepatic encephalopathy subscores were
dichotomized (1 = normal or below cutpoint, 2 = abnor-
mal or above cutpoint) was also evaluated for its
performance.
Exploratory Analyses
Cox proportional hazard models were fit utilizing age,
gender, three-point ascites subscore, three-point albumin
subscore (using 3.6 and 3.3 g/dl cutpoints), and three-point
total bilirubin subscore (2.9 and 3.3 mg/dl cutpoints) with
several variations: three-point versus two-point INR strat-
ification (1.8/4.5 vs. 3.3), three-point versus two-point
encephalopathy stratification (standard vs. absent/present),
and inclusion of a two-point serum creatinine (sCr) sub-
score using a cutpoint of 1.8 mg/dl derived from serial
iteration of the models. A creatinine-mCTP model (mCTP-
Cr) eliminating INR was then iterated in serial Cox models
to identify cutpoints for all three laboratory variables to
identify the model yielding the highest Harrell’s C-statistic.
To assess each model’s concordance for predicting out-
come across the range of clinical severity, oCTP, mCTP,
mCTP-Cr, and MELD were assessed in serial subgroups of
the cohort defined by three-level oCTP ranges (e.g., 5–7,
6–8, 7–9, …, 13–15) or defined by MELD ranges (6–10,
7–11, 8–12, …., 36–40).
Results
Demographics of the VOCAL cohort with prevalent cir-
rhosis during the first quarter 2008 have been previously
described [16]. The cohort consists of predominantly well-
compensated, white (72.3 %) male (97.2 %) cirrhotic
patients. The dominant non-exclusive underlying liver dis-
eases include hepatitis C infection (48.8 %) and alcohol
abuse/dependence (62.6 %); 18.7 % have cirrhosis not
attributable to alcohol or viral hepatitis. The median MELD
score was 10. Median eCTP class/score was A6, and 43 %
were eCTP B7 or higher. For this cohort, at least 5 years of
follow-up for death or transplantation were available.
To screen for the directionality of changes in individual
laboratory cutpoints, we first ran Cox proportional hazard
models to estimate concordance of mCTP scores altering the
upper and lower limits of each of the three laboratory vari-
ables INR, serum albumin, and total bilirubin while fixing
the other two variable cutpoints at the original values. As
shown in Fig. 1 (triangles), varying the lower INR cutpoint
over a wide range identified optimal prediction at 1.8, very
similar to the existing cutpoint of 1.7. By contrast, the
optimal value for the upper INR cutpoint was significantly
greater than the existing 2.3, plateauing at approximately 4.5.
For serum albumin, an upper cutpoint of 3.6 g/dl, similar to
the existing 3.5 g/dl cutpoint, yielded optimal concordance.
However, a lower cutpoint of 3.3 g/dl, significantly higher
than the existing 2.8 g/dl, appeared optimal. Varying the
lower cutpoint of total bilirubin over a wide range showed an
initial peak of concordance at 1.3 mg/dl and second higher
peak at 2.9 mg/dl, both significantly better than the current
2.0 mg/dl lower cutpoint. Marginally improved predictive
capacity of the upper bilirubin cutpoint from the existing
3.0–3.3 mg/dl improved performance; further increases
yielded no predictive improvement.
The optimal cutpoints were further refined by varying each
single variable while fixing the other two variables at the
newly identified optimal cutpoints. As shown in Fig. 1 (cir-
cles), estimates for optimal cutpoints for each of the labora-
tory components of the CTP score did not significantly
change but the overall predictive capacity of the mCTP
increased to approximately 0.709 ± 0.002 from 0.701 ±
0.002 with the oCTP model. The cutpoints for the final pro-
posed mCTP and the oCTP are summarized in Table 1.
Using the optimized cutpoints in a multivariable Cox
proportional hazard model including age, and the five CTP
subscores with or without including gender in the model
[Table 2(A)], serum albumin, total bilirubin, and ascites
subscores had the greatest contribution (LogWorth) to the
risk prediction of the CTP model. For these three param-
eters, incremental risk ratios for a one score (none) to two
(mild or medically controlled) to three (severe or medically
refractory) increased in a relatively linear fashion with
relative risks (RR) of 1.5–1.6 for scores of 2 and 2.1–3.2
for scores of 3. Encephalopathy scores showed a modest
increased RR for a score of 2 [RR 1.2 (95 % CI 1.1–1.3)]
and a further modest increase for a score of 3 [RR 1.8
(95 % CI 1.7–1.9)]. INR showed an extremely modest
increase in the RR of death or transplant for a score of 2
[RR 1.3 (95 % CI 1.2–1.4)] and no significant impact for a
score of 3. Given the low RR for scores of 3 and overall
small contribution to the CTP model, we designed a second
mCTP model dichotomizing encephalopathy (1 = absent,
2 = present) and INR. To identify the appropriate single
cutpoint for INR in a two-level model, we calculated
Harrell’s C-statistics varying INR over the range from 1 to
6.5 while varying albumin and total bilirubin cutpoints over
narrower ranges (Fig. 4 in ‘‘Appendix’’); we found that
INR cutpoints from 3.1 to 4.0 optimized discriminative
capacity. Our simplified mCTP (mCTP13) using an INR
cutpoint of 3.3 (for consistency with albumin and total
bilirubin cutpoints) is shown in Table 1. The Harrell’s
C-statistic for age- and gender-adjusted mCTP13 in the first
quarter of 2008 cohort was identical to the mCTP
(0.709 ± 0.002) with a significantly higher hazard ratio
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1.60 (95 % CI 1.58–1.61) than the mCTP [1.53 (95 % CI
1.52–1.54)].
We next investigated the utilization of sCr in mCTP
models. Serial Cox proportional hazard models adding a
lower and upper cutpoint for sCr factor were iterated over
the range of sCr from 1.0 to 7.0 (Fig. 1d). These models
showed that the optimal C-statistic was achieved using a
lower sCr cutpoint of 1.8 and upper cutpoint of 2.3 mg/dl.
After inclusion of sCr, the INR subscore no longer was
statistically significantly associated with 5-year TFS (data
not shown), so a simplified model was created substituting
INR with sCr. To evaluate the impact of this change on the
other two laboratory cutpoints, we iterated upper and lower
cutpoints for total bilirubin and serum albumin over a wide
range to assess trends. We found that optimal cutpoints for
albumin did not change (3.6 and 3.3 g/dl), the lower total
bilirubin cutpoint did not change (2.9 mg/dl), but the
optimal upper total bilirubin cutpoint increased up to
3.7 mg/dl. The final model (mCTP-Cr) is shown in
Table 1. In multivariable Cox analysis [Table 2(B)], the
Fig. 1 Impact of varying upper
and lower cutoffs of CTP
laboratory variables on
concordance (Harrell’s C) for
prediction of 5-year transplant-
free survival. a–c For each
simulation, one variable was
modified while fixing the other
five variables at either original
cutpoints (triangle), modified
optimized cutpoints (open
circle) or intermediate values
(diamond). Arrowhead shows
optimal cutpoint defined around
original CTP cutpoints for other
five variables. Filled triangle
represents original CTP, and
filled circle represents modified
CTP. d Effect of iterating serum
creatinine cutpoints in
creatinine-modified CTP model.
Arrowhead indicates point of
optimal concordance
3312 Dig Dis Sci (2016) 61:3309–3320
123
HRs for creatinine subscores 2 and 3 were 1.6 (1.5–1.7)
and 2.1 (1.9–2.2), respectively. The HR for a bilirubin
score of 3 increased slightly with the new upper cutpoint.
Using these modifications, the C-statistic for the mCTP-Cr
model improved to 0.712 ± 0.002 (Table 3).
The performance of the oCTP, mCTP, and mCTP-Cr in
predicting 5-year transplant-free survival was validated
using datasets for patients in the cohort in the subsequent
three quarters of 2008 (Table 3) and compared with
MELD, VACS, and Huo CTP (Table 5 in ‘‘Appendix’’).
All CTP-based models were more predictive for 5-year
transplant-free survival than MELD or VACS. The Huo
CTP modification had a negligible difference from the
oCTP. For cohorts drawn from each quarter, overall con-
cordance of mCTP, mCTP13, and mCTP-Cr exceeded that
of oCTP and these were highly similar. Hazard ratios for
mCTP13 were significantly greater than mCTP due to the
narrower range of scores (5–13 compared to 5–15).
Kaplan–Meier survival curves for oCTP, mCTP, and
mCTP-Cr (Fig. 4 in ‘‘Appendix’’) show that mCTP elimi-
nates cross-over in survival curves for oCTP 12–13.
Across disease classes, mCTP and mCTP-Cr had sta-
tistically superior predictive capacity than oCTP particu-
larly for individuals with alcoholic and non-viral cirrhosis
(Table 4). mCTP and mCTP-Cr had statistically superior
predictive capacity than oCTP and MELD in non-black
men (Table 6 in ‘‘Appendix’’), but was not statistically
better in the relatively small African-American subset of
patients. Due to limited numbers, no differences in per-
formance in women were shown for mCTP and mCTP-Cr
relative to oCTP, but all three models were superior to
MELD. In addition, CTP-based predictive systems were
markedly better at predicting 5-year transplant-free sur-
vival in individuals with MELD lower than 15, a group
generally not considered for transplantation referral based
on relatively low short-term mortality. Additionally, mCTP
and mCTP-Cr performed better than oCTP or MELD for
predicting shorter term 1-, 2-, 3- and 4-year transplant-free
survival (Table 7 in ‘‘Appendix’’).
To assess the predictive performance of mCTP, mCTP-
Cr relative to oCTP and MELD, we analyzed serial subsets
of the cohort over increasing MELD or oCTP score ranges
(Fig. 2). We found that over MELD ranges 12–16 to
27–31, mCTP and mCTP-Cr exhibited higher concordance
than oCTP. At MELD 28–32, mCTP and oCTP converge,
but mCTP-Cr remains statistically superior until MELD
30–34, beyond which small cohort sizes limit the ability to
differentiate model performance. Even at high MELD
scores, CTP-based models better predict 5-year TFS (and
1–4-year TFS, data not shown). Over serial binning of the
cohort by oCTP ranges (Fig. 2b), mCTP and mCTP-Cr
maintain superior concordance for ranges from oCTP 6–8
to 9–11. For patients with oCTP 9–11, mCTP, oCTP, and
MELD converge. Above an oCTP 11–13, mCTP-Cr has
superior predictive capacity than mCTP or oCTP. For
patients with oCTP 11–13, 12–14 or 13–15, MELD best
predicts death or transplant events. Fewer than 2 % of
cirrhotic patients were alive in these oCTP classes during
the index quarter. Thus, among the models mCTP-Cr
maintains the greatest degree of predictive consistency
across the spectrum of liver disease severity.
Discussion
The CTP score, while developed to predict portosystemic
shunt surgery outcomes in cirrhotic patients [2, 3], histor-
ically has remained the most widely used staging system to
predict long-term survival in cirrhosis [1]. Despite wide-
spread acceptance, several flaws of CTP as a prognostic
staging system have been identified [26]. It relies on two
subjective assessments, fostering inter-observer variation
Table 1 Laboratory cutpoints for original CTP (oCTP), modified 5–15 CTP (mCTP), second modified CTP system dichotomizing INR and
encephalopathy (mCTP13) and creatinine-modified CTP (mCTP-Cr)
Subscore oCTP mCTP
INR Albumin (g/dl) Total bilirubin (mg/dl) INR Albumin (g/dl) Total bilirubin (mg/dl)
1 \1.7 [3.5 \2.0 \1.8 [3.6 \2.9
2 1.7–2.3 2.8–3.5 2.0–3.0 1.8–4.5 3.3–3.6 2.9–3.3
3 [2.3 \2.8 [3.0 [4.5 \3.3 [3.3
mCTP13
a mCTP-Cr
INR Albumin (g/dl) Total bilirubin (mg/dl) Serum creatinine (mg/dl) Albumin (g/dl) Total bilirubin (mg/dl)
1 B3.3 [3.6 \2.9 \1.8 [3.6 \2.9
2 [3.3 3.3–3.6 2.9–3.3 1.8–2.3 3.3–3.6 2.9–3.7
3 \3.3 [3.3 [2.3 \3.3 [3.7
a Encephalopathy subscore (1 = none, 2 = present)
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and hampering application to large datasets. The cutpoints
for the objective laboratory variables have never been
validated. Additionally, the dynamic range of the CTP with
only 11 total strata and three classes theoretically reduces
its utility for prioritization in organ allocation. We have
previously shown that by creating operational definitions
for ascites and encephalopathy based on ICD9-CM diag-
nosis codes, CPT procedure codes, laboratory and phar-
macy refill data, and the subjective variables of the CTP
score can be estimated (eCTP) with a high degree of pre-
cision [16]. In this study, which represents the largest
dataset used to evaluate CTP to date, the electronic oCTP
was significantly more accurate than MELD or VACS
scores for predicting 1–5-year transplant-free survival.
Addition of comorbidity indices such as Charlson–Deyo
and CirCom [18] had minimal impact on prediction.
Our cohort of 30,897 cirrhotic subjects with prevalent
cirrhosis in the first quarter of 2008 who have at least
5 years of follow-up allows for robust modeling to deter-
mine evidence-based, optimal CTP cutpoints. One striking
finding on multivariable Cox proportional hazard modeling
was that cutpoint estimation for INR, albumin, bilirubin
and creatinine were highly independent suggesting that
these three measures truly reflect different aspects of the
pathophysiology of end-stage liver disease associated with
outcome.
The lower bound of INR associated with increased
mortality risk was adequately estimated by the oCTP score.
The similarity of the lower cutpoint we identified as optimal
and the original value is notable, approximating a pro-
thrombin time [4 s longer than control. However, the
original upper cutpoint of 2.3 (based on a prothrombin time
6 s longer than control) does not appear to have intrinsic
validity; increased risk of death was more closely associated
with significantly higher degrees of coagulopathy. INR only
modestly contributes to CTP in multivariable Cox propor-
tional hazard models as a three-level factor. Indeed, a single
cutpoint at INR between 3.1 and 3.5 better discriminated the
degree of coagulopathy associated with increased risk of
death or transplantation. Eliminating patients on warfarin
did not impact these findings (data not shown).
Dichotomizing the INR subscore (1 = INR\3.3, 2 = INR
C3.3) also did not negatively impact predictive capacity.
Notably, this cutpoint is nearly identical to that identified by
Asrani and Kim [27] as the point at which increasing INR
no longer is associated with increasing mortality. Our data
strongly support the clinical gestalt that by the time in the
natural history of cirrhosis at which significant INR
increases are observed, the prognosis is so poor that further
increases have little impact on observed survival.
Many clinicians consider declining albumin to be the
most sensitive marker of progressive liver dysfunction, both
as a reflection of impaired synthetic reserve and as a pre-
cursor of the neurohumoral response that results in ascites
and hepatorenal syndrome. Indeed, relatively modest
reductions in albumin (3.7–3.8) from normal markedly
increased risk of mortality. Nonetheless, the optimal upper
cutpoint of 3.6 g/dl from our cohort approximated the
originally chosen value of 3.5 g/dl. Strikingly however,
high risk was imparted at serum albumin values much
higher than the original 2.8 g/dl, occurring at a lower cut-
point of 3.3 g/dl. Seventeen percent of the cohort had serum
albumin values of 2.8–3.2 g/dl and were given an additional
point by the mCTP. Median survival for individuals with
albumin 2.8–3.2 was significantly shorter [907 days (95 %
CI 872–943)] than for those with albumin 3.3–3.5
[1629 days (95 % CI 1569–1700)]. Given the marked dis-
parity in survival of individuals with albumin levels in the
lower half of the oCTP albumin score 2 range (2.8–3.2 vs.
3.3–3.5), raising the lower cutpoint of albumin to 3.3 g/dl
Table 3 Performance of
original CTP (oCTP), modified
CTP (mCTP), simplified
modified CTP (mCTP13), and
creatinine-modified CTP
(mCTP-Cr) in predicting 5-year
transplant-free survival in
cohorts drawn from 2008
quarters 1–4
Quarter N Events oCTP mCTP
HR Harrel’s C HR Harrel’s C
Q1 30,897 15,275 1.50 (1.49–1.52) 0.701 ± 0.002 1.53 (1.52–1.54) 0.709 ± 0.002
Q2 31,033 15,515 1.48 (1.47–1.49) 0.694 ± 0.002 1.52 (1.51–1.54) 0.705 ± 0.002
Q3 30,989 15,521 1.48 (1.47–1.49) 0.700 ± 0.002 1.51 (1.50–1.52) 0.708 ± 0.002
Q4 30,218 15,287 1.49 (1.48–1.50) 0.702 ± 0.002 1.53 (1.52–1.54) 0.712 ± 0.002
Quarter N Events mCTP13 mCTP-Cr
HR Harrel’s C HR Harrel’s C
Q1 30,897 15,275 1.60 (1.58–1.61) 0.709 ± 0.002 1.57 (1.56–1.59) 0.712 ± 0.002
Q2 31,033 15,515 1.59 (1.57–1.60) 0.705 ± 0.002 1.57 (1.55–1.58) 0.708 ± 0.002
Q3 30,989 15,521 1.57 (1.56–1.59) 0.707 ± 0.002 1.56 (1.54–1.57) 0.711 ± 0.002
Q4 30,218 15,287 1.60 (1.58–1.61) 0.712 ± 0.002 1.57 (1.55–1.58) 0.714 ± 0.002
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appears to be alteration of the oCTP that yields the greatest
magnitude of improvement in model performance.
We observed a bimodal behavior of the lower bilirubin
cutoff, in which a cutpoint of 1.3 mg/dl was superior to the
current 2.0 mg/dl cutpoint, but an even stronger concor-
dance was generated using a higher cutpoint of 2.9 mg/dl.
By contrast with the MELD, there was a relatively low
transition to a high-risk bilirubin value at 3.3 mg/dl [27].
We could not replicate an improvement of prediction by
addition of points to the CTP for very high bilirubin levels
([8 mg/dl) as proposed by Huo et al. [24] either in the
complete cohort or those with decompensated cirrhosis
(Table 7 in ‘‘Appendix’’). These data are in concordance
with the relatively low weighting of total bilirubin in the
MELD score, but differ from the linear association with
mortality observed over a large dynamic range of total
bilirubin when utilized in MELD models [27]. We ulti-
mately found that in mCTP-Cr the optimal cutpoints were
2.9 and 3.7 mg/dl.
The inclusion of ‘‘subjective’’ assessments of HE and
ascites has been a consistent critique of the CTP scoring
system [26]. However, both ascites and HE have been
shown to have a strong impact on survival [28–30] and
quality of life in end-stage liver disease [31] but correlate
poorly with MELD score [30–32]. Encephalopathy is very
difficult to quantify administratively [33], and the lack of
impact of a higher score could reflect misclassification or
could reflect lack of internal validity for a three-level
Table 4 Performance of original CTP (oCTP) and modified CTP (mCTP) in predicting 5-year transplant-free survival in specific disease
etiology subsets
Disease N Events oCTP mCTP mCTP-Cr
HR Harrel’s C HR Harrel’s C HR Harrel’s C
HCV, no EtOH 5549 2075 1.68 (1.64–1.73) 0.735 ± 0.006 1.77 (1.72–1.81) 0.740 ± 0.006 1.80 (1.75–1.86) 0.741 ± 0.006
EtOH, no HCV 9755 5165 1.39 (1.36–1.41) 0.668 ± 0.004 1.42 (1.40–1.44) 0.680 ± 0.004 1.46 (1.44–1.48) 0.682 ± 0.004
HCV ? EtOH 9533 5066 1.50 (1.48–1.52) 0.707 ± 0.004 1.51 (1.49–1.53) 0.710 ± 0.004 1.56 (1.54–1.59) 0.712 ± 0.004
HBV 589 240 1.64 (1.52–1.76) 0.727 ± 0.019 1.77 (1.63–1.91) 0.740 ± 0.019 1.82 (1.67–1.99) 0.738 ± 0.019
Other 5777 2872 1.45 (1.42–1.49) 0.711 ± 0.005 1.57 (1.53–1.61) 0.726 ± 0.005 1.63 (1.60–1.68) 0.732 ± 0.005
Fig. 2 Impact of varying clinical severity on concordance of oCTP,
mCTP, mCTP-Cr, and MELD on 5-year transplant-free survival.
a The 2008 quarter 1 cohort was serially subsetted by five-point
MELD ranges and the C-statistics for oCTP (solid gray), mCTP (solid
lack), mCTP-Cr (dashed gray, solid marker), and MELD (dashed
black) plotted. The percentage of patients in each subset is plotted on
the secondary axis (gray dotted line, round marker). b The 2008
quarter one cohort was serially subsetted by three-point oCTP ranges
and the C-statistics for oCTP (solid gray), mCTP (solid lack), mCTP-
Cr (dashed gray, solid marker), and MELD (dashed black) plotted.
The percentage of patients in each subset is plotted on the secondary
axis (gray dotted line, round marker)
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stratification. Dichotomizing the CTP encephalopathy
subscore (1 = absent, 2 = present) based on hospitaliza-
tions and/or treatment for HE might simplify and reduce
the subjectivity of this assessment. We found that doing so
had no significant impact on the predictive capacity of CTP
models (C-statistic 0.709 ± 0.002 for both three- and two-
level models). Similarly, the Mayo group found that there
was no statistical difference in Kaplan–Meier survival rates
for HE grades of 2 or 3 [30]. However, in mCTP-Cr a
three-level encephalopathy score proved superior (data not
shown). The presence of encephalopathy ICD9 codes or
medications remains critical to CTP for predictive capacity
and partially explains the improved performance of CTP
over MELD in predicting survival in this and other cohorts
[16, 30]. A similar simplification of ascites scoring wors-
ened CTP predictive capacity; however, the strict opera-
tional definition we used for severe or refractory ascites,
which required [1 large-volume paracentesis in the pre-
ceding 90 days or history of TIPSS placement, could
strongly reduce the subjectivity of this assessment in
practice.
Strengths of our study include large cohort size, com-
pleteness of follow-up for outcomes, and variety of disease
etiologies. The limitations of this study, similar to the
original derivation cohort, include the predominance of
male patients and complexity of the eCTP algorithm, that
requires access to claims, laboratory and pharmacy data.
Therefore, replicating this study requires comprehensive
administrative datasets. External validation of the mCTP
and mCTP-Cr score on non-VA administrative datasets
would be important before recommending a wholesale
change of the 50-year-old CTP scoring system.
Conclusion
The mCTP and creatinine-modified mCTP-Cr models show
superiority over oCTP and MELD in predicting 1-, 2-, 3-, 4- and
5-year transplant-free survival in a large cohort of cirrhotic
individuals ranging from well to poorly compensated. Aug-
menting the clinical gestalt of highly skilled and experienced
liver surgeons that has stood the test of time with modern evi-
dence-based estimates based on survival models can improve
the capacity of CTP to predict short- and long-term survival in
multiple cirrhosis etiologies and demographic subsets. We
recommend modifying the CTP score used in clinical practice
to incorporate the current evidence-based cutpoints.
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Appendix
See Tables 5, 6 and 7, Figs. 3 and 4.
Table 5 Performance of original CTP (oCTP), modified CTP
(mCTP), simplified modified CTP (mCTP13), Taiwanese-proposed
modification of CTP (Huo CTP), model for end-stage liver disease
(MELD), Veteran’s Aging Cohort Study (VACS) in predicting 5-year
transplant-free survival in specific disease etiology subsets
Regressor Unit HR Harrell’s C R2 LR test Wald Logrank
eCTP per unit change 1.49 (1.48–1.50) 0.701 ± 0.002 0.213 7394 8711 9188
mCTP per unit change 1.53 (1.52–1.54) 0.709 ± 0.002 0.232 8172a 9842 10,413
mCTP13 per unit change 1.60 (1.58–1.61) 0.709 ± 0.002 0.231 8110
a 9330 9939
mCTP-Cr per unit change 1.57 (1.56–1.59) 0.712 ± 0.002 0.242 8563a 10,225 10,687
Huo CTP per unit change 1.47 (1.46–1.48) 0.695 ± 0.002 0.211 7306 8716 8974
MELD per unit change 1.10 (1.09–1.10) 0.639 ± 0.002 0.110 3608a 4230 4240
VACS per 10 unit change 1.32 (1.31–1.33) 0.670 ± 0.002 0.156 5246a 5602 5605
eCTP class B versus A 2.48 (2.40–2.57) 0.682 ± 0.002 0.180 6132 6925 8112
C versus A 7.35 (6.96–7.77)
mCTP class B versus A 2.80 (2.71–2.90) 0.693 ± 0.002 0.205 7090 8004 9564
C versus A 8.91 (8.42–9.43)
mCTP-Cr class B versus A 2.88 (2.79–2.98) 0.690 ± 0.002 0.196 6733 7514 8845
C versus A 9.84 (9.21–10.50)
a p\ 0.0001 for difference of LR test by ANOVA with eCTP
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Table 6 Performance of




(mCTP-Cr), and model for end-
stage liver disease (MELD) in
predicting 5-year transplant-free
survival in specific demographic
subgroups
Subgroup Regressor HR Harrell’s C R2 LR test
Race = white oCTP 1.47 (1.46–1.49) 0.695 ± 0.003 0.207 5182
n = 22,325 mCTP 1.51(1.50–1.53) 0.705 ± 0.003 0.229 5820
Events = 11,361 mCTP-Cr 1.56 (1.55–1.58) 0.708 ± 0.003 0.240 6118
MELD 1.10 (1.10–1.10) 0.635 ± 0.003 0.107 2535
Race = black oCTP 1.61 (1.57–1.65) 0.723 ± 0.007 0.231 1164
n = 4434 mCTP 1.64 (1.60–1.69) 0.726 ± 0.007 0.236 1196
Events = 1835 mCTP-Cr 1.69 (1.64–1.73) 0.730 ± 0.007 0.250 1275
MELD 1.11 (1.10–1.12) 0.661 ± 0.007 0.130 519
Race = other oCTP 1.47 (1.44–1.51) 0.703 ± 0.006 0.214 997
n = 4138 mCTP 1.51 (1.47–1.55) 0.715 ± 0.006 0.237 1118
Events = 2079 mCTP-Cr 1.56 (1.53–1.60) 0.717 ± 0.002 0.247 1171
MELD 1.09 (1.08–1.10) 0.641 ± 0.006 0.108 475
Males oCTP 1.49 (1.47–1.50) 0.699 ± 0.002 0.211 7136
n = 30,060 mCTP 1.53 (1.51–1.54) 0.708 ± 0.002 0.231 7900
Events = 14,974 mCTP-Cr 1.57 (1.56–1.59) 0.711 ± 0.002 0.240 8265
MELD 1.10 (1.09–1.10) 0.637 ± 0.002 0.108 3428
Females oCTP 1.62 (1.52–1.72) 0.726 ± 0.017 0.214 201
n = 837 mCTP 1.66 (1.56–1.77) 0.725 ± 0.017 0.226 214
Events = 301 mCTP-Cr 1.77 (1.66–1.90) 0.729 ± 0.017 0.247 237
MELD 1.17 (1.14–1.19) 0.683 ± 0.017 0.153 139
eCTP[7 oCTP 1.41 (1.38–1.44) 0.627 ± 0.004 0.125 936
n = 7035 mCTP 1.39 (1.36–1.42) 0.648 ± 0.004 0.152 1157
Events = 5418 mCTP-Cr 1.42 (1.40–1.45) 0.658 ± 0.004 0.175 1355
MELD 1.05 (1.04–1.06) 0.574 ± 0.004 0.156 142
Huo CTP 1.38 (1.35–1.40) 0.639 ± 0.004 0.147 1122
MELD\15 oCTP 1.54 (1.52–1.57) 0.669 ± 0.003 0.134 3121
n = 23,739 mCTP 1.55 (1.53–1.58) 0.676 ± 0.003 0.145 3396
Events = 10,251 mCTP-Cr 1.58 (1.56–1.59) 0.680 ± 0.003 0.155 4010
MELD 1.10 (1.09–1.11) 0.588 ± 0.003 0.040 891
Huo CTP 1.49 (1.47–1.51) 0.662 ± 0.003 0.125 2907
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